ASCLF (Ascletis Pharma) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ascletis Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Ascletis Pharma's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Ascletis Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ascletis Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma LT-Debt-to-Total-Asset Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial												-	-	-	-	-

Ascletis Pharma LT-Debt-to-Total-Asset Calculation

Ascletis Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.191	/	291.809
	=	0.00

Ascletis Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.191	/	291.809
	=	0.00

Ascletis Pharma (OTCPK:ASCLF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ascletis Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

01672:Hong Kong 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.